Italian guidelines for the management of infectious complications in pediatric oncology: Empirical antimicrobial therapy of febrile neutropenia

Oncology

Volumn 55, Issue 5, 1998, Pages 489-500

  Viscoli, C ^a,b   Castagnola, E ^a   Caniggia, M ^a   De Sio, L ^a   Garaventa, A ^a   Giacchino, M ^a   Indolfi, P ^a   Izzi, G C ^a   Manzoni, P ^a   Rossi, M R ^a   Santoro, N ^a   Zanazzo, G A ^a   Masera, G ^a  

^a Infectious Disease Section   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Cancer; Fever; Neutropenia; Pediatrics; Therapy

Indexed keywords

AMINOGLYCOSIDE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; GLYCOPEPTIDE;

BLOOD CULTURE; CHILDHOOD CANCER; DRUG COST; DRUG TOXICITY; FEVER; HUMAN; INFECTIOUS COMPLICATION; ITALY; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THORAX RADIOGRAPHY; THROAT CULTURE; URINE CULTURE;

EID: 17144470505     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011901     Document Type: Review

References (70)

1. Chang HY, Rodriguez V, Narboni G, Bodey GP, Luna MA, Freireich EJ: Causes of death in adults with acute leukemia. Medicine 1976;55: 259-268.
2. Feld R, Bodey GP: Infections in patients with malignant lymphoma treated with combination chemotherapy. Cancer 1977;39:1018-1025.
3. Klastersky J, Zinner SH, Calandra T, Gaya H, Glauser MP, Meunier F, et al.: Empiric antimicrobial therapy for febrile, granulocytopenic cancer patients: lesson from 4 EORTC trials. Eur J Cancer Clin Oncol 1988;24:S35-S45.
4. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards J, Feld R, et al.: Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-573.
5. Katz JA, Mustafa MM: Management of fever in granulocytopenic children with cancer. Pediat Infect Dis J 1993;12:330-339.
6. Feld R: The role of surveillance cultures in patients likely to develop chemotherapy-induced mucositis. Supportive Care Cancer 1997;5:371-375.
7. Martino P, Girmenia C, Venditti M, Micozzi A, Santilli S, Burgio VL, et al.: Candida colonization and systemic infection in neutropenic patients. A retrospective study. Cancer 1989; 64:2030-2034.
8. Feusner J, Cohen R, O' Leary M, Beach B: Use of routine chest radiography in the evaluation of fever in neutropenic pediatric oncology patients. J Clin Oncol 1988;6:1699-1702.
9. Katz JA, Mustafa MM, Bash RO, Cash JV, Buchanan GR: Value of C-reactive protein determination in the initial diagnostic evaluation of the febrile, neutropenic child with cancer. Pediat Infect Dis J 1992;11:708-712.
10. Donowitz GR, Harman C, Pope T, Stewart FM: The role of the chest roentgenogram in febrile neutropenic patients. Arch Intern Med 1991;151:701-704.
11. Paisley JW, Lauer BA: Pediatric blood cultures. Clinics Lab Med 1994;14:17-30.
12. Weinstein MP: Current blood culture methods and systems: clinical concepts, technology and interpretation of results. Clin Infect Dis 1996; 23:40-46.
13. Ligtenberg PC, Hoepelman IM, Oude Sogtoen GA, Dekker AW, van der Tweel I, Rozenberg Arska M, et al.: C-reactive protein in the diagnosis and management of infections in granulocytopenic and non-granulocytopenic patients. Eur J Microbiol Infect Dis 1991;10:25-31.
14. Rintala E, Irjala K, Nikoskelainen J: Value of measurement of C-reactive protein in febrile patients with hematologic malignancies. Eur J Microbiol Infect Dis 1992;11:973-978.
15. Tasso L, Castagnola E, Fiore P, Garaventa A, Dini G, Dallorso S, et al.: Prognostic Inflammatory and Nutritional Index (PINI) in the evaluation of management of febrile granulocytopenic children. In Program and Abstr 6th Int Congr Infectious Diseases, Prague 1994, p 369 (abstract 1187).
16. Manian FA: A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia. Clin Infect Dis 1995; 21:114-121.
17. Pizzo P, Rubin M, Freifield A, Walsh T: The child with cancer and infection. I. Empiric therapy for fever and neutropenia and preventive strategies. J Pediat 1991;119:679-694.
18. Wiernikowski JT, Rothney M, Dawson S, Andrew M: Evaluation of a home intravenous antibiotic program in pediatric oncology. Am J Pediat Hematol Oncol 1991;13:144-147.
19. Martino P, Girmenia C, Raccah R, Micozzi A, Cimino G, Sgadari C, et al.: Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology 1992;49:49-52.
20. Rubinstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, et al.: Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71:3640-3646.
21. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R: Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:07-114.
22. Gardembas-Pain M, Desablens B, Sensebe L, Lamt T, Ghandour C, Boasson M: Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol 1991;2:485-487.
23. Malik IA, Khan WA, Aziz Z, Karim M: Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with non-hematologic neoplasms. Clin Infect Dis 1994;19:522-527.
24. Viscoli C, Dudley M, Ferrea G, Boni L, Castagnola E, Barretta MA, et al.: Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. J Antimicrob Chemother 1991; 27(suppl C):113-120.
25. Talcott JA, Siegel RD, Finberg R, Goldman L: Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10:316-322.
26. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, et al.: Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-396.
27. Rains CP, Bryson HM, Peters DH: Ceftazidime. An update on its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1995;49:577-617.
28. Cometta A, Zinner S, de Bock R, Calandra T, Gava H, Klastersky J, et al.: Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995;39:445-452.
29. EORTC IATCG: Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119: 584-593.
30. Winston DJ, Winston GH, Bruckner DA, Champlin RE: Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991;115: 849-859.
31. Pizzo P, Hathorn JV, Hiemenz J, Browne M, Commers J, Cotton D, et al.: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-558.
32. de Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly P: Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 1994;120:834-844.
33. Freifield AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, et al.: Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165-176.
34. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, et al.: Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996;40:1108-1115.
35. EORTC IATCG: Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987;317:1692-1698.
36. Gold HS, Moellering RC: Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-1453.
37. Karp JE, Dick C, Angelopulos C, Charache P, Green L, Burke R, et al.: Empiric use of vancomycin during prolonged treatment induced granulocytopenia. Randomized double-blind, placebo controlled trial in patients with acute leukemia. Am J Med 1986;81:237-242.
38. Del Favero A, Menichetti F, Guerciolini R, Bucaneve G, Baldelli F, Aversa F, et al.: Prospective randomised clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile granulocytopenic acute leukemia patient. Antimicrob Agents Chemother 1987;31: 1126-1129.
39. Shenep J, Hughes WT, Robertson PK, Blankenship K, Baker D, Meyer WH, et al.: Vancomycin, ticarcillin and amikacin compared with ticarcillin- clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988;319: 1053-1058.
40. Rubin M, Hathorn JV, Marshall D, Gress J, Steinberg SM, Pizzo P: Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30-35.
41. Viscoli C, Moroni C, Boni L, Bruzzi P, Comelli A, Dini G, et al.: Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis 1991;13:397-404.
42. EORTC IATCG: Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-958.
43. Micozzi A, Nucci M, Venditti M, Gentile G, Girmenia C, Meloni G, et al.: Piperacillin/tazobactam/amikacin versus piperacillin/tazobactam/amikacin/ teicoplanin in the empirical treatment of neutropenic patients. Eur J Microbiol Infect Dis 1993;12:1-8.
44. Anonimous: Beta-lactamases; in Lambert HP, O'Grady FW (eds): Antibiotic and chemotherapy. London, Churchill Livingstone, 1992, pp 80-83.
45. Anonimous: Carbapenems; in Lambert HP, O' Grady FW (eds): Antibiotic and chemotherapy. London, Churchill Livingstone, 1992, pp 74-77.
46. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson M, et al.: Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-590.
47. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ: Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporin. Ann Intern Med 1993;119:353-358.
48. Blaser J, Koenig C, Simmen HP, Thurnheer U: Monitoring serum concentrations for once-daily netilmicin dosing regimens. J Antimicrob Chemother 1994;33:341-348.
49. Prins JM, Koopmans RP, Bueller HR, Kuijper EJ, Speelman P: Easier monitoring of aminoglycoside therapy with once-daily dosing schedules. Eur J Microbiol Infect Dis 1995;14:531-535.
50. Pizzo P: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-1332.
51. Lucas KG, Brown AE, Armstrong D, Chapman D, Heller G: The identification of febrile, neutropenic children at low risk for bacteremia and complications of sepsis. Cancer 1996;77:791-798.
52. Di Nubile MJ: Stopping antibiotic therapy in neutropenic patients. Ann Intern Med 1988; 108:289-292.
53. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-111.
54. Mullen CA, Buchanan GR: Early discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient. J Clin Oncol 1990;8:1998-2004.
55. Kaplan AH, Weber DJ, Davis L, Israel F, Wells RJ: Short courses of antibiotics in selected febrile neutropenic patients. Am J Med Sci 1991;302:353-354.
56. Griffin TC, Buchanan GR: Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: implications for discontinuation of antibiotics and early discharge from the hospital. J Pediat 1992;121: 28-33.
57. Bash RO, Katz JA, Cash JV, Buchanan GR: Safety and cost-effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994;74:189-196.
58. Tomiak AT, Yau JC, Huan SD, Cripps MC, Goel R, Perrault DJ, et al.: Duration of intravenous antibiotics for patients with neutropenic fever. Ann Oncol 1994;5:441-445.
59. Cohen KJ, Learner K, Odom L, Greffe B, Stork L: Cessation of antibiotics regardless of ANC is safe in children with febrile neutropenia. J Pediat Hematol Oncol 1995;17:325-330.
60. Sundararajan V, Rubinstein EB, Rolston K, Elting LS: Controversies in new antibiotic therapy for ambulatory patients. Supportive Care Cancer 1997;5:358-364.
61. Lau RC, Doyle JJ, Freedman MH, King SM, Richardson SE: Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Pediat Hematol Oncol 1994;11:417-421.
62. EORTC IATCG: Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-672.
63. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, et al.: Fungal infections in cancer patients: an international autopsy survey. Eur J Microbiol Infect Dis 1992;11:99-109.
64. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K: Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32.
65. Aisner J, Schimpff S, Wiernik H: Treatment of invasive aspergillosis: relation of early diagnosis and treatment response. Ann Intern Med 1977;86:539-543.
66. Burke PJ, Braine HG, Rathbun HK, Owens AHJ: The clinical significance and management of fever in acute myelocytic leukemia. John Hopkins Med J 1976;139:1-12.
67. Castagnola E, Bucci B, Montinaro E, Viscoli C: Fungal Infections in patients undergoing hone marrow transplantation: an approach to a rational management protocol. Bone Marrow Transplant 1996;18:97-106.
68. Viscoli C, Castagnola E, Machetti M: Antifungal treatment in patients with cancer. J Intern Med 1997;242:89-94.
69. Viscoli C, Castagnola E, Van Lint MT, Moroni C, Garaventa A, Rossi MR, et al.: Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996;32A:814-820.
70. Van Bunk JH, Bowden RA: Standard antifungal treatment, including roles of alternative modalities to administer amphotericin B. Baillière's Clin Infect Dis 1995;2:89-109.